Any current/future new fundraising through debt or equity?

Morepen Laboratories recently completed a significant equity fundraising round, raising approximately ₹565 crores through promoter subscriptions and external investors like Corinth investing $32.5 million directly into Morepen (Pages 14-15). The total targeted fundraise is around ₹750 crores, with 75% going to Morepen (Page 14). The company plans to utilize these funds primarily for four projects including API expansion, diagnostic devices, and formulation (Page 15). No plans currently to raise debt; the company is debt-free except for preference capital which is to be redeemed (Page 12). Expa

Any current/future capex/capital investment/strategic investment?

Morepen Laboratories has a significant expansion plan with a total investment of around Rs. 178 crores for a new API production block, expected to be commercialized over 3 years in phases. An additional Rs. 55 crores is allocated to setting up a new R&D center focused on new molecules for APIs and Finished Dosage formulations. Plans include expanding diagnostic devices and Finished Dosage segments: - Diagnostic devices business is growing exponentially and will be spun off as a separate subsidiary. - Finished Dosage expansion with a Rs. 100 crore CAPEX for automatic packaging and machining

Future growth expectations in sales/revenue/volumes?

Morepen Laboratories aims to sustain and continue its growth trajectory across all business segments. The company targets a revenue run rate of around ₹1200 crores annually, with quarterly averages around ₹300 crores. Device business expects exponential growth in next 3 years, targeting ₹2000 crores production value in 3-5 years. Capex plans of ₹150 crores and ₹100 crores for expansion in API and Finished Dosage segments respectively, over 2-3 years. Plans to grow diagnostic devices from current 5 million meters installed, targeting broader market penetration, including tier 3/4 cities. ANDAs

Future growth expectations in earnings/operating earnings/profits/EPS?

Management is confident of continuing the growth trajectory, supported by sustainability and a well-geared team (Page 17). Currently, EBITDA margin is around 11%, below typical pharma range of 18-20%, indicating room for margin improvement as exports and forward integration into Finished Dosages increase (Page 17). Long-term plans include ramping up API, Diagnostic Devices, Finished Dosage, and OTC segments, with significant CAPEX and R&D investments to support growth (Pages 16, 8). Expansion projects expected to raise production capacity and product pipeline; aiming for revenue values of Rs.

Morepen Laboratories LtdQ4 FY21Pharmaceuticals & Biotechnology

Morepen Laboratories Ltd Q4 FY21 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹119.31P/E: 55.5Market Cap: ₹6.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

Yes

3 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

Morepen Laboratories aims to sustain and continue its growth trajectory across all business segments.
The company targets a revenue run rate of around ₹1200 crores annually, with quarterly averages around ₹300 crores.
Device business expects exponential growth in next 3 years, targeting ₹2000 crores production value in 3-5 years.
Capex plans of ₹150 crores and ₹100 crores for expansion in API and Finished Dosage segments respectively, over 2-3 years.
Plans to grow diagnostic devices from current 5 million meters installed, targeting broader market penetration, including tier 3/4 cities.
ANDAs filing and R&D focus anticipate new product launches in diabetics and cardiac markets by 2025-26.
Increased online presence with plans to expand from 100 to 500 (health and wellness) products in 3 years.
Regulatory approvals and environmental clearances support expansion projects aiming for full commercial production in 3 years.
COVID-related demand may normalize, but overall lifestyle changes signal sustained growth in diagnostics.

Margin guidance

Category 1

Management is confident of continuing the growth trajectory, supported by sustainability and a well-geared team (Page 17).
Currently, EBITDA margin is around 11%, below typical pharma range of 18-20%, indicating room for margin improvement as exports and forward integration into Finished Dosages increase (Page 17).
Long-term plans include ramping up API, Diagnostic Devices, Finished Dosage, and OTC segments, with significant CAPEX and R&D investments to support growth (Pages 16, 8).
Expansion projects expected to raise production capacity and product pipeline; aiming for revenue values of Rs. 2000-4000 crores over next 3-5 years from devices and formulations (Pages 10, 8).
EPS rose 189% last year to Rs. 2.16 per share, indicating strong profit growth, with management optimistic about sustaining upward trends despite pandemic-related market fluctuations (Pages 10, 17).
Equity infusion of approx Rs. 565 crores planned to fund expansion, signaling commitment to scaling operations and profitability (Page 15).

See what Morepen Laboratories Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Morepen Laboratories recently completed a significant equity fundraising round, raising approximately ₹565 crores through promoter subscriptions and external investors like Corinth investing $32.5 million directly into Morepen (Pages 14-15).
The total targeted fundraise is around ₹750 crores, with 75% going to Morepen (Page 14).
The company plans to utilize these funds primarily for four projects including API expansion, diagnostic devices, and formulation (Page 15).
No plans currently to raise debt; the company is debt-free except for preference capital which is to be redeemed (Page 12).
Expansion and CAPEX are funded through internal accruals and equity infusion, avoiding additional banking debt (Pages 8, 12).
CAPEX worth ₹178 crores for the new API block is being completed in phases over the next 2-3 years (Page 13).

Order book

The provided transcript from Morepen Laboratories Limited does not explicitly mention details about the current or expected order book or pending orders. However, some relevant points related to business growth and capacity expansion include: - The company is gearing up for major growth with multiple business segments: API, Diagnostic Devices, Finished Dosage, and OTC. - They have an ongoing CAPEX plan, including a ₹178 crore API expansion project and a ₹100 crore Finished Dosage project expected to complete by 2025-26. - Export business is strong, contributing about 39% of total revenue, with API exports growing 44% and diagnostic devices by 71%. - The company highlights new customer additions (103 customers) and expanding to over 80 countries. - Expected product pipeline includes 13 ANDAs nearing various stages of development and significant R&D investments. - The company is confident of a continued growth trajectory fueled by expansion and market opportunities. No explicit order book or pending order value was disclosed.

See what Morepen Laboratories Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Morepen Laboratories has a significant expansion plan with a total investment of around Rs. 178 crores for a new API production block, expected to be commercialized over 3 years in phases.
An additional Rs. 55 crores is allocated to setting up a new R&D center focused on new molecules for APIs and Finished Dosage formulations.
Plans include expanding diagnostic devices and Finished Dosage segments:
- Diagnostic devices business is growing exponentially and will be spun off as a separate subsidiary.
- Finished Dosage expansion with a Rs. 100 crore CAPEX for automatic packaging and machining lines, targeting diabetic and cardiac product markets, expected over 2 years.
Total investment funding combines internal accruals, promoter equity infusion (Rs. 300 crores), and external investor funding (e.g., Rs. 32.5 million from Corinth).
New projects, including API expansion and diagnostic device development, have approvals in place; land acquisition underway.

Track Morepen Laboratories Ltd — get its next earnings analysis in your feed

How does Morepen Laboratories Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisMorepen Laboratories Ltd

Rev 2Mar 1

See where Morepen Laboratories Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Morepen Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Morepen Laboratories Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY21) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Morepen Laboratories Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →